{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-268497","form_type":"8-K","ticker":"XOMA","cik":"0000791908","company_name":"XOMA Royalty Corp","filed_at":"2024-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.029787+00:00","generated_at":"2026-05-29T12:26:43.139912+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"XOMA Royalty acquires Pulmokine for $20M, adding seralutinib royalty/milestone interest","bullets":["Acquisition of Pulmokine for $20M cash at closing plus success-based consideration.","XOMA gets low- to mid-single-digit net royalty on seralutinib commercial sales.","XOMA retains up to $25M of future milestone payments tied to seralutinib.","Seralutinib (Phase 3 PAH) readout expected Q4 2025; developed by Gossamer/Chiesi.","This is XOMA's second whole-company acquisition in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-268497","json":"https://secwatch.observer/filing/0001193125-24-268497.json","markdown":"https://secwatch.observer/filing/0001193125-24-268497.md","text":"https://secwatch.observer/filing/0001193125-24-268497.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/791908/000119312524268497/0001193125-24-268497-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/791908/000119312524268497/d900185d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T12:26:43.139912+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}